Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study

Ruth Van Daele; Joost Wauters; Erwin Dreesen; Jerina Boelens; Eric Nulens; Piet Lormans; Lore Vanderbeke; Cato Jacobs; Bart Rijnders; Paul E Verweij; Roger J Brüggemann; Isabel Spriet

doi:10.1111/myc.13446

Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study

Ruth Van Daele^*
, Joost Wauters
, Erwin Dreesen
, Jerina Boelens
, Eric Nulens
, Piet Lormans
, Lore Vanderbeke
, Cato Jacobs
, Bart Rijnders
, Paul E Verweij
, Roger J Brüggemann
, Isabel Spriet

^*Corresponding author for this work

University Hospitals Leuven
KU Leuven
Ghent University Hospital
Department of Anesthesiology and Intensive Care Medicine
Amalia Children’s Hospital
AZ St-Jan Bruges-Ostend AV Hospital

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

BACKGROUND: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population.

METHODS: In this observational sub-study, we performed a pharmacokinetic analysis, including protein binding and target attainment (TA). Blood samples were collected over a 24 h-dosing interval on both an early (Day 2 or 3) and a later (≥Day 4) treatment day.

RESULTS: Target attainment was shown for AUC0-24 and Cmin prophylaxis but not for Cmin treatment. Moreover, a saturable protein binding with a significant, positive relationship between albumin concentrations and the maximum binding capacity was observed.

CONCLUSIONS: Our analysis indicates that posaconazole may be a suitable drug to further investigate for prophylaxis, as TA for prophylaxis was reached. Exposure targets for treatment were insufficiently attained in this population.

Original language	English
Pages (from-to)	656-660
Number of pages	5
Journal	Mycoses
Volume	65
Issue number	6
Early online date	19 Apr 2022
DOIs	https://doi.org/10.1111/myc.13446
Publication status	Published - Jun 2022

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/myc.13446

Cite this

@article{b2fc1c21c7a04ea4b4c43b79221617c5,

title = "Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study",

abstract = "BACKGROUND: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population.METHODS: In this observational sub-study, we performed a pharmacokinetic analysis, including protein binding and target attainment (TA). Blood samples were collected over a 24 h-dosing interval on both an early (Day 2 or 3) and a later (≥Day 4) treatment day.RESULTS: Target attainment was shown for AUC0-24 and Cmin prophylaxis but not for Cmin treatment. Moreover, a saturable protein binding with a significant, positive relationship between albumin concentrations and the maximum binding capacity was observed.CONCLUSIONS: Our analysis indicates that posaconazole may be a suitable drug to further investigate for prophylaxis, as TA for prophylaxis was reached. Exposure targets for treatment were insufficiently attained in this population.",

author = "\{Van Daele\}, Ruth and Joost Wauters and Erwin Dreesen and Jerina Boelens and Eric Nulens and Piet Lormans and Lore Vanderbeke and Cato Jacobs and Bart Rijnders and Verweij, \{Paul E\} and Br{\"u}ggemann, \{Roger J\} and Isabel Spriet",

note = "{\textcopyright} 2022 Wiley-VCH GmbH.",

year = "2022",

month = jun,

doi = "10.1111/myc.13446",

language = "English",

volume = "65",

pages = "656--660",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

TY - JOUR

T1 - Exposure to intravenous posaconazole in critically ill patients with influenza

T2 - A pharmacokinetic analysis of the POSA-FLU study

AU - Van Daele, Ruth

AU - Wauters, Joost

AU - Dreesen, Erwin

AU - Boelens, Jerina

AU - Nulens, Eric

AU - Lormans, Piet

AU - Vanderbeke, Lore

AU - Jacobs, Cato

AU - Rijnders, Bart

AU - Verweij, Paul E

AU - Brüggemann, Roger J

AU - Spriet, Isabel

PY - 2022/6

Y1 - 2022/6

N2 - BACKGROUND: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population.METHODS: In this observational sub-study, we performed a pharmacokinetic analysis, including protein binding and target attainment (TA). Blood samples were collected over a 24 h-dosing interval on both an early (Day 2 or 3) and a later (≥Day 4) treatment day.RESULTS: Target attainment was shown for AUC0-24 and Cmin prophylaxis but not for Cmin treatment. Moreover, a saturable protein binding with a significant, positive relationship between albumin concentrations and the maximum binding capacity was observed.CONCLUSIONS: Our analysis indicates that posaconazole may be a suitable drug to further investigate for prophylaxis, as TA for prophylaxis was reached. Exposure targets for treatment were insufficiently attained in this population.

AB - BACKGROUND: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population.METHODS: In this observational sub-study, we performed a pharmacokinetic analysis, including protein binding and target attainment (TA). Blood samples were collected over a 24 h-dosing interval on both an early (Day 2 or 3) and a later (≥Day 4) treatment day.RESULTS: Target attainment was shown for AUC0-24 and Cmin prophylaxis but not for Cmin treatment. Moreover, a saturable protein binding with a significant, positive relationship between albumin concentrations and the maximum binding capacity was observed.CONCLUSIONS: Our analysis indicates that posaconazole may be a suitable drug to further investigate for prophylaxis, as TA for prophylaxis was reached. Exposure targets for treatment were insufficiently attained in this population.

UR - https://www.scopus.com/pages/publications/85128879059

U2 - 10.1111/myc.13446

DO - 10.1111/myc.13446

M3 - Article

C2 - 35437848

SN - 0933-7407

VL - 65

SP - 656

EP - 660

JO - Mycoses

JF - Mycoses

IS - 6

ER -

Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this